» Articles » PMID: 37065332

Does Type 2 Diabetes Increase the Risk of Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease Patients? A Systematic Review

Overview
Journal Cureus
Date 2023 Apr 17
PMID 37065332
Authors
Affiliations
Soon will be listed here.
Abstract

Diabetes is associated with different types of cancers of which hepatocellular carcinoma (HCC) is one among them. In a study comparing patients with diabetes to those who do not have diabetes, it was evident that the risk of HCC is found to increase two-fold in diabetic than that in non-diabetic patients. It is clear that carcinogenesis is advanced due to diabetes in the liver by a variety of mechanisms. We searched PubMed and Google Scholar for articles from 2010 to 2021 that have an association between diabetes, nonalcoholic fatty liver disease (NAFLD), and HCC. For the development of HCC, diabetes is likely related at both the molecular and epidemiological levels. Both diabetes mellitus and hepatic malignancy have the worst impact on mankind socioeconomically. There is a significant relationship between diabetes and HCC independent of alcohol consumption and viral hepatitis. It is noteworthy that not only the elderly but also people of all age groups should monitor their hemoglobin A1C levels. Diet restriction and lifestyle modification can reduce the risk of complications like HCC; the increased physical activity itself can have a major influence on health and can manage comorbidities like diabetes, NAFLD, and HCC.

Citing Articles

Both Maternal High-Fat and Post-Weaning High-Carbohydrate Diets Increase Rates of Spontaneous Hepatocellular Carcinoma in Aged-Mouse Offspring.

Holt D, Contu L, Wood A, Chadwick H, Alborelli I, Cacciato Insilla A Nutrients. 2024; 16(16).

PMID: 39203941 PMC: 11357072. DOI: 10.3390/nu16162805.

References
1.
Ertle J, Dechene A, Sowa J, Penndorf V, Herzer K, Kaiser G . Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2010; 128(10):2436-43. DOI: 10.1002/ijc.25797. View

2.
Wang C, Wang X, Gong G, Ben Q, Qiu W, Chen Y . Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. Int J Cancer. 2011; 130(7):1639-48. DOI: 10.1002/ijc.26165. View

3.
Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021; 10(1):89. PMC: 8008539. DOI: 10.1186/s13643-021-01626-4. View

4.
Than N, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H . Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM. 2016; 110(2):73-81. PMC: 5444673. DOI: 10.1093/qjmed/hcw151. View

5.
Amiri Dash Atan N, Koushki M, Motedayen M, Dousti M, Sayehmiri F, Vafaee R . Type 2 diabetes mellitus and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2018; 10(Suppl1):S1-S7. PMC: 5838173. View